Literature DB >> 19945431

Requirement of T-lymphokine-activated killer cell-originated protein kinase for TRAIL resistance of human HeLa cervical cancer cells.

Hyeok-Ran Kwon1, Ki Won Lee, Zigang Dong, Kyung Bok Lee, Sang-Muk Oh.   

Abstract

T-lymphokine-activated killer cell-originated protein kinase (TOPK) appears to be highly expressed in various cancer cells and to play an important role in maintaining proliferation of cancer cells. However, the underlying mechanism by which TOPK regulates growth of cancer cells remains elusive. Here we report that upregulated endogenous TOPK augments resistance of cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis inducing ligand (TRAIL). Stable knocking down of TOPK markedly increased TRAIL-mediated apoptosis of human HeLa cervical cancer cells, as compared with control cells. Caspase 8 or caspase 3 activities in response to TRAIL were greatly incremented in TOPK-depleted cells. Ablation of TOPK negatively regulated TRAIL-mediated NF-kappaB activity. Furthermore, expression of NF-kappaB-dependent genes, FLICE-inhibitory protein (FLIP), inhibitor of apoptosis protein 1 (c-IAP1), or X-linked inhibitor of apoptosis protein (XIAP) was reduced in TOPK-depleted cells. Collectively, these findings demonstrated that TOPK contributed to TRAIL resistance of cancer cells via NF-kappaB activity, suggesting that TOPK might be a potential molecular target for successful cancer therapy using TRAIL. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945431     DOI: 10.1016/j.bbrc.2009.11.147

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  The role of T-LAK cell-originated protein kinase in targeted cancer therapy.

Authors:  Lu Zhang; Fei Wang; Huijun Yi; Svetlana P Ermakova; Olesya S Malyarenko; Jianmei Mo; Yingze Huang; Qiuhong Duan; Juanjuan Xiao; Feng Zhu
Journal:  Mol Cell Biochem       Date:  2022-01-17       Impact factor: 3.396

2.  Phosphorylation of IκBα at serine 32 by T-lymphokine-activated killer cell-originated protein kinase is essential for chemoresistance against doxorubicin in cervical cancer cells.

Authors:  Jung-Hwan Park; Dae-Sung Yoon; Hye-Jin Choi; Dae-Hyun Hahm; Sang-Muk Oh
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

3.  Death Receptors: New Opportunities in Cancer Therapy.

Authors:  V M Ukrainskaya; A V Stepanov; I S Glagoleva; V D Knorre; A A Jr Belogurov; A G Gabibov
Journal:  Acta Naturae       Date:  2017 Jul-Sep       Impact factor: 1.845

4.  Identification of the oncogenic kinase TOPK/PBK as a master mitotic regulator of C2H2 zinc finger proteins.

Authors:  Raed Rizkallah; Paratchata Batsomboon; Gregory B Dudley; Myra M Hurt
Journal:  Oncotarget       Date:  2015-01-30

5.  Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase.

Authors:  Mengzhu Zheng; Shanshan Luan; Suyu Gao; Li Cheng; Bin Hao; Jiacheng Li; Yao Chen; Xuemei Hou; Lixia Chen; Hua Li
Journal:  Oncotarget       Date:  2017-06-13

6.  Role of TOPK in lipopolysaccharide-induced breast cancer cell migration and invasion.

Authors:  Min-Ah Seol; Jung-Hwan Park; Ji Heun Jeong; Jungmook Lyu; Seung Yun Han; Sang-Muk Oh
Journal:  Oncotarget       Date:  2017-06-20

7.  Immunometabolic and potential tumor-promoting changes in 3D cervical cell models infected with bacterial vaginosis-associated bacteria.

Authors:  Jason D Maarsingh; Paweł Łaniewski; Melissa M Herbst-Kralovetz
Journal:  Commun Biol       Date:  2022-07-22

8.  TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.

Authors:  Ying Li; Zhiwei Yang; Weijie Li; Shudi Xu; Tao Wang; Ting Wang; Mengjie Niu; Shengli Zhang; Lintao Jia; Shengqing Li
Journal:  Oncotarget       Date:  2016-02-09

Review 9.  T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.

Authors:  Katharine J Herbert; Thomas M Ashton; Remko Prevo; Giacomo Pirovano; Geoff S Higgins
Journal:  Cell Death Dis       Date:  2018-10-24       Impact factor: 8.469

10.  PBK attenuates paclitaxel-induced autophagic cell death by suppressing p53 in H460 non-small-cell lung cancer cells.

Authors:  Jung-Hwan Park; Sang-Ah Park; Young-Ju Lee; Hwan-Woo Park; Sang-Muk Oh
Journal:  FEBS Open Bio       Date:  2020-04-14       Impact factor: 2.693

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.